Becker's Healthcare October 23, 2024
Alexandra Murphy

The FDA approved Pfizer’s Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

The approval is based on data from Pfizer’s Phase 3 MONeT trial, which evaluated the vaccine’s safety and efficacy in high-risk adults, according to an Oct. 22 news release from...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
This is what might happen if the US withdraws from the WHO
Opinion: Allowing ICE in hospitals is a public health catastrophe in the making
How Donald Trump Is Reshaping Global Health
InnovationRx: The Impact Of Trump’s Withdrawal From The WHO And His Other Healthcare Orders
Critical Steps To Address Climate, Health, And Equity

Share This Article